Esperion Therapeutics Liabilities 2024

Esperion Therapeutics Aktienanalyse

What does Esperion Therapeutics do?

Esperion Therapeutics Inc is a company specialized in researching and developing innovative therapies for the treatment of heart diseases. It was founded in 2008 and is headquartered in Ann Arbor, Michigan. History: The founding of Esperion is closely connected with the history of another pharmaceutical company, Pfizer. In 2003, Pfizer introduced the drug Lipitor, used for treating high cholesterol levels. Lipitor quickly became one of the most successful medications worldwide, generating billions in revenue over the following years. Esperion Therapeutics Inc was founded to develop an alternative to Lipitor that would be better tolerated and potentially more effective. The company relied on the expertise of Dr. Roger Newton, the former research director at Pfizer involved in the development of Lipitor. Business model: Esperion's business model is based on acquiring patents for new compounds and then investigating these compounds in clinical trials. If a compound shows promise, Esperion can apply for approval from the US Food and Drug Administration (FDA) and bring the medication to market. The company has also formed a partnership with Daiichi-Sankyo to market its products in Japan and other Asian countries. Segments: Esperion focuses on developing therapies for the treatment of hyperlipidemia, or high cholesterol levels. This means the company develops medications that lower LDL cholesterol levels and reduce the risk of heart and vascular diseases. One promising compound from Esperion is ETC-1002. This medication is currently being tested in clinical trials and has the potential to be an effective alternative to conventional statins, as it does not have the same undesired effects. Other products: Esperion also has a division called Esperion Diabetes Solutions, which focuses on developing therapies for the treatment of type 2 diabetes. However, this is still in the development stage. Additionally, the company has another compound in clinical development called Bempedoic Acid. This medication acts at the cellular level to inhibit cholesterol synthesis in the body. Conclusion: Esperion Therapeutics is a company specializing in the development of innovative therapies for the treatment of heart diseases. The company focuses on lowering LDL cholesterol levels and reducing the risk of heart and vascular diseases. Esperion's promising product is ETC-1002, which has the potential to be an effective alternative to conventional statins. Through its partnership with Daiichi-Sankyo, the company also has access to Asian markets. Esperion Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Esperion Therapeutics's Liabilities

Esperion Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Esperion Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Esperion Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Esperion Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Esperion Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Esperion Therapeutics Stock

What is the level of liabilities of Esperion Therapeutics this year?

Esperion Therapeutics has a debt balance of 660.79 M USD this year.

What were the liabilities of Esperion Therapeutics compared to the previous year?

The liabilities of Esperion Therapeutics have increased by 15.58% increased compared to the previous year.

What are the consequences of high debt for investors of Esperion Therapeutics?

High liabilities can pose a risk for investors of Esperion Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Esperion Therapeutics?

Low liabilities mean that Esperion Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Esperion Therapeutics affect the company?

An increase in liabilities of Esperion Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Esperion Therapeutics affect the company?

A decrease in the liabilities of Esperion Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Esperion Therapeutics?

Some factors that can influence the liabilities of Esperion Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Esperion Therapeutics so important for investors?

The liabilities of Esperion Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Esperion Therapeutics take to modify the liabilities?

To change its liabilities, Esperion Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Esperion Therapeutics pay?

Over the past 12 months, Esperion Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Esperion Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Esperion Therapeutics?

The current dividend yield of Esperion Therapeutics is .

When does Esperion Therapeutics pay dividends?

Esperion Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Esperion Therapeutics?

Esperion Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Esperion Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Esperion Therapeutics located?

Esperion Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Esperion Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Esperion Therapeutics from 7/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.

When did Esperion Therapeutics pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of Esperion Therapeutics in the year 2023?

In the year 2023, Esperion Therapeutics distributed 0 USD as dividends.

In which currency does Esperion Therapeutics pay out the dividend?

The dividends of Esperion Therapeutics are distributed in USD.